bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
journals.plos.org /6 days ago

Allosteric inhibition rescues hydrocephalus caused by catalytically inactive Shp2 in mice

by Neoklis Makrides, Emily Sun, Hilal Mir, Jen-Zen Chuang, Ziyuan Jiang, Yihua Wu, Carlos Serra, John Peregrin, Qian Wang, Wellington V. Cardoso, Ching-Hwa Sung, Neel H. Shah, Xin...

Read source
aacr.org /2 weeks ago

Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cance...

Read source
journals.plos.org /1 month ago

Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical <i>KRAS</i> var...

by Michael D. Nicholson, Ian Tomlinson Hypermutant cancers frequently contain atypical driver gene variants, which may provide sub-optimal oncogenic advantages. The reason why wea...

Read source
journals.plos.org /3 days ago

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhib...

Read source
journals.plos.org /1 month ago

Altered regulation of septal peptidoglycan synthesis modulates β-lactam susceptibility in <i>Pseudomonas aeruginos...

by Jake Colautti, Alexander C. Anderson, Wyatt P. K. Clark, Lindsey S. Marmont Bacterial cell division requires precise regulation of septal peptidoglycan (PG) synthesis by the es...

Read source
bioengineer.org /1 month ago

Platinum Chemotherapy, Not PARP Inhibitors, Emerges as the Main Driver of Blood Clone Expansion

New research shows carboplatin drives the expansion of TP53-mutant blood clones far more strongly than PARP inhibitors, while inherited homologous recombination deficiency unexpect...

Read source
journals.plos.org /2 weeks ago

A common pathogenic founder variant in Rwandan breast cancer cases

by Achille V. C. Manirakiza, Shakuntala Baichoo, Annette Uwineza, Damas Dukundane, Eulade Rugengamanzi, Janviere Mutamuliza, Allison M. O. Niragira, Raissa Muvunyi, Jeffrey Besada,...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.